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Abstract
Background: Here, we evaluated the hypothesis that CD8+ T cell responses to caspase-cleaved antigens derived
from effector T cells undergoing apoptosis, may contribute to multiple sclerosis (MS) immunopathology.
Methods: The percentage of autoreactive CD8+ T effector cells specific for various apoptotic T cell-associated
self-epitopes (apoptotic epitopes) were detected in the peripheral blood and cerebrospinal fluid (CSF) by both
enzyme-linked immunospot and dextramers of class I molecules complexed with relevant apoptotic epitopes.
Moreover, the capacity of dextramer+ CD8+ T cells to produce interferon (IFN)-γ and/or interleukin (IL)-17 in
response to the relevant apoptotic epitopes was evaluated by the intracellular cytokine staining. Cross-presentation
assay of apoptotic T cells by dendritic cells was also evaluated ex vivo.
Results: We found that polyfunctional (IFN-γ and/or IL-17 producing) autoreactive CD8+ T cells specific for
apoptotic epitopes were represented in MS patients with frequencies significantly higher than in healthy donors.
These autoreactive CD8+ T cells with a strong potential to produce IFN-γ or IL-17 in response to the relevant
apoptotic epitopes were significantly accumulated in the CSF from the same patients. In addition, the frequencies
of these autoreactive CD8+ T cells correlated with the disease disability. Cross-presentation assay revealed that
caspase-cleaved cellular proteins are required to activate apoptotic epitope-specific CD8+ T cells ex vivo.
Conclusion: Taken together, these data indicate that apoptotic epitope-specific CD8+ T cells with strong
inflammatory potential are recruited at the level of the inflammatory site, where they may be involved in MS
immunopathology through the production of high levels of inflammatory cytokines.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory demye-
linating disease representing a major cause of neurological
disability in the Western world [1]. Genetics, environmen-
tal factors - in particular the Epstein-Barr virus (EBV),
and autoimmune steps are believed to be involved in MS
development [1-4].
T helper (Th)1 cells were initially thought to be the
only effector (memory) T cells (TEM) [5,6] capable of
mediating inflammatory demyelination in MS [7]; how-
ever, the discovery of Th17 cells has led to the idea that
IL-17 produced by CD4+ or CD8+ T cells specific to
myelin proteins (likely in response to IL-23 and granulo-
cyte monocyte-colony stimulating factor, GM-CSF) plays
a preponderant role in the autoimmune demyelinating
disease found in humans and mice [8-15]. The administra-
tion of IFN-β [16,17], the oral drug fingolimod (FTY-720)
[18], or hematopoietic stem cell transplantation [19] has
been associated with a reduction in Th17 responses that
parallels clinical improvement.
Dendritic cells (DCs) that are also present in brain
lesions and in the cerebrospinal fluid (CSF), can take up
antigens (particularly from apoptotic cells), and migrate
to the deep cervical lymph nodes for the priming
or cross-priming of naive CD4+ or CD8+ T cells, respec-
tively [20-26]. Recently, similar cross-presentation capacity
and phagocytic function have been shown in all human
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lymphoid organ-resident DCs (including BDCA1+, BD
CA3+ and the plasmocytoid DCs), confuting the observa-
tion proposing that BDCA1+ DCs (shown to be the homo-
logues of mouse CD8+ DCs) cross-present antigens more
efficiently than other blood DC subsets [27]. Whether
DCs found in brain lesions or CSF belong to one or more
of the DC subsets described above, or to monocyte-
derived inflammatory DCs (recently demonstrated in various
inflammatory environments [27]) is an important issue to
investigate. We have previously shown that myelin basic
protein (MBP)-specific T cells produce IFN-γ in response
to autologous DCs loaded with apoptotic oligodendro-
cytes in vitro [28]. This result indicated that myelin-
specific antigens presented within the apoptotic glial cells
may be involved in the first relevant MS pathogenetic step.
However, other steps may need to be carried out to initi-
ate or aggravate the autoimmune process in the disease.
In the present study, we consider the fate of the large
number of apoptotic cells resulting from the rapid turn-
over of effector T cells undergoing apoptosis after
performing their functions in inflammatory diseases, and
the possible role of these apoptotic cells in MS. In previ-
ous studies, we demonstrated that the proteome of apop-
totic T cells include prominent caspase-cleaved cellular
proteins (namely, fragments of actin cytoplasmic 1
(ACTB) [Swissprot: P60709], heterogeneous nuclear ribo-
nucleoprotein (ROK) [Swissprot: P61978], lamin B1
(LAM1) [Swissprot: P20700], non-muscle myosin heavy
chain 9 (MYH9) [Swissprot: P35579], vimentin (VIME)
[Swissprot: P08670], proteasome component C2 (PSA1)
[Swissprot: P25786], rho GDP dissociation inhibitor 2
(GDIS) [Swissprot: P50395], and 60S acidic ribosomal pro-
tein P2 (RLA) [Swissprot: P05387]), and a high proportion
of distinct epitopes in these fragments (apoptotic epitopes)
can be cross-presented by DCs via the classical major
histocompatibility complex (MHC) class I pathway to a
wide repertoire of autoreactive CD8+ T cells [25,29]. This
observation led us to demonstrate that caspases within
apoptotic cells can cleave fragments from long-lived pro-
teins [30] that are strictly anchored to cellular structures
(for example, the cytoskeleton); these fragments are then
efficiently phagocytosed, processed, and cross-presented
by DCs [25]. Further reports have confirmed the role of
caspase cleavage in the processing and presentation of epi-
topes that are derived from apoptotic cells in different
models [31-33]. In addition, apoptotic cells derived from
activated T cells retain the expression of CD40 ligand (L)
and can condition CD40+ DCs to acquire high capacities
to prime or cross-prime autoreactive T cells [25,29,34].
This mechanism is consistent with the evidence that the
signals provided by CD40L+ apoptotic cells and not those
provided by conventional apoptotic cells (that generally
induce immune tolerance or resolution of inflammation)
facilitate the emergence of autoreactive T cell responses to
apoptotic self-antigens [35,36]. In chronic HIV or hepatitis
C virus (HCV) infections, the proportion of resulting
autoreactive CD8+ T cells correlates with the proportion
of circulating apoptotic CD4+ T cells in vivo and with the
disease progression [25,29]. Research has suggested that
the emergence and the maintenance of these responses
contribute to amplification of the immunopathology
through their capacity to produce high levels of inflamma-
tory cytokines [25,29,34].
The aims of the present study are to determine
whether CD8+ T cells specific for apoptotic self-epitopes
are prominent in MS patients, to verify whether they
have a distinct effector phenotype, to distinguish which
of them is associated with the disease severity, and to as-




For the present study, 26 consecutive HLA-A2+ MS pa-
tients (median age 40 years, range 19 to 61 years), who had
presented for a diagnostic evaluation or relapse of MS at
two neurological institutions during a 1-year period, were
recruited; 20 of the patients were female. They were exam-
ined in accordance with the ethical guidelines of the 1975
Declaration of Helsinki and with a priori approval by the
Ethics Committee of the Italian National Institute of
Health. Written informed consent was obtained from all
patients. The clinical and paraclinical characteristics of the
patients included in this study are shown in Table 1. In-
clusion criteria were as follows: MS diagnosis defined
according to the McDonald criteria [37], the absence of an
immunosuppressive therapy, and HLA-A2 positivity. All
patients consented to the study and no patients were lost to
follow up. The Expanded Disability Status Scale (EDSS)
scores ranged from 1.0 to 6.0 (mean 2.6). The clinical
course was classified as relapsing-remitting in twenty-four
patients, whereas two patients had secondary-progressive
MS. Ten patients were treated with glatiramer acetate or
IFN-β, whereas sixteen patients did not receive any
immunomodulating, immunosuppressive, or steroid ther-
apy. Magnetic resonance imaging (MRI) was performed
for each patient within 30 days from sampling. Nine pa-
tients presented with gadolinium-enhanced MRI lesions
suggestive of blood-brain barrier damage. A lumbar punc-
ture was performed in 15 of the 26 patients. With the ex-
ception of one subject, all displayed CSF oligoclonal
immunoglobulin G (IgG) bands after CSF IgG isoelectric
focusing in accordance with the recommended procedures.
No patient was undergoing therapy with steroids or im-
munosuppressive drugs in the three months prior to sam-
pling. All patients were subjected to clinical/paraclinical
follow up from the time of diagnosis. Buffy coats from
HLA-A2+ 27 sex and age-matched healthy donors (HDs)
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were provided by the blood bank of Dipartimento di
Immunoematologia e Medicina Trasfusionale (Sapienza
Università di Roma).
Synthetic peptides and reagents
Ninety-one HLA-2 binding peptides (nonamers or deca
mers) were derived from caspase-cleaved fragments of
ACTB, ROK, LAM1, MYH9, VIME, PSA1, GDIS, and
RLA as previously described (Additional file 1: Table
S1). Seventeen 21-mer overlapping peptides spanning
the entire human MBP sequence [Swissprot: P02686-5]
were synthesized by high performance liquid chromatog-
raphy (HPLC). The purity of peptides was determined
by reverse-phase HPLC (Additional file 2: Table S2).
Cell preparations
Peripheral blood mononuclear cells (PBMCs) were isolated
and T cell lines were generated as previously described
[23]. CD8+ T cells were purified from PBMCs by positive
selection coupled to magnetic beads (Miltenyi Biotec,
Bologna, Italy) [38]. Flow cytometry analysis demon-
strated > 99% CD8+ cells in the positively purified
population and < 5% in the CD8-depleted population.
Spontaneous apoptosis of T cells from patients was
determined by staining fresh PBMCs with fluorescein
isothiocyanate (FITC)-labeled Annexin-V (Biolegend),
propidium iodide (PI) (Biolegend, London, UK) and
allophycocyanin (APC)-labeled anti-CD3 monoclonal
antibody (mAb) (Biolegend). Immature (i)DCs were
derived from peripheral monocytes and generated as
described. Monocyte-derived iDCs were purified by
positive selection with anti-CD14 mAb coupled to
magnetic beads (MiltenyiBiotec). CD14+ cells were in-
cubated for 5 days in Roswell Park Memorial Institute
(RPMI) 1640 medium containing 10% FCS, 2 mM glutam-
ine, 1% nonessential amino acids, 1% sodium pyruvate, 50
μg/ml kanamycin (Gibco BRL), 50 ng/mL recombinant (r)
GM-CFS (PeproTech, DBA, Segrate - Milano, Italy), and
Table 1 Main demographic, clinical and MRI characteristics of HLA-A2+ patients
Patient Gender Age Duration (years) Predominant symptoms MRI Gd enhancement EDSS
1 F 48 1 motor - 6
2 F 20 2 brainstem, ON + 2
3 F 51 4 brainstem + 3
4 F 29 3 cerebellar, sensitive + 3
5 F 37 1 brainstem - 1
6 F 53 7 brainstem - 0
7 F 40 1 sensitive - 2
8 M 39 1 cerebellar - 1
9 F 40 2 ON - 1
10 F 38 1 ON, sensitive - 2
11 M 49 1 ON - 1
12 F 46 1 sensitive - 1
13 M 24 1 sensitive, ON - 1
14 M 49 20 motor, ataxia - 4
15 F 43 1 sensitive - 2
16 F 34 2 sphincteric, ON + 3
17 F 61 5 brainstem, vertigo - 1
18 F 40 3 sensitive - 3
19 M 43 2 motor - 5
20 F 35 1 motor - 1
21 F 43 5 motor - 4
22 M 32 6 motor + 7
23 F 53 4 motor, ataxia + 4
24 F 19 1 brainstem + 1
25 F 43 9 sensitive, brainstem + 2
26 F 53 4 sensitive, motor + 3
All patients had relapsing remitting MS, except for patients 1 and 14 who had secondary-progressive MS.
Legend: ON, optic neuritis; EDSS, expanded disability status scale; MRI Gd enhancement, nuclear magnetic resonance gadolinium enhancement.
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1000 U/mL rIL-4 (generously provided by A Lanzavecchia,
Bellinzona, CH). Mature DCs were obtained by a 40-h
stimulation of iDCs with soluble rCD40L molecules (Enzo
Life Sciences, Vinci-Biotech, Vinci - Firenze, Italy). The
definition of monocyte-derived DCs was based on their
surface phenotype profile by staining with anti-CD14, anti-
CD86 (Caltag Laboratories), anti-CD1a, anti-CD1c, anti-
CD11c, anti-CD32, anti-CD80 (BD PharMingen, Milano,
Italy) mAbs.
Enzyme-linked immunospot assay
After stimulation with 12 independent pools of apoptotic
peptides (Additional file 1: Table S1) or 16 single MBP
peptides (Additional file 2: Table S2) PBMCs were tested
by enzyme-linked immunospot (ELISPOT) assay. Briefly,
96-well millimeter high-affinity plates (Millipore Corpor-
ation, Bedford, MA, USA) were coated with 10 μg/mL of
capture mAb against IFN-γ (BD PharMingen) at 4°C
overnight. Plates were blocked for 2 h with blocking so-
lution (PBS containing 2% BSA). A total of 1 × 105
PBMCs were added to each well and stimulated for 18 h
with peptides. Biotinylated anti-IFN-γ (BD PharMingen)
diluted to 5 μg/mL in Blocking Solution was added and
incubated for 2 h in 5% CO2 at 37°C. Plates were washed,
incubated with alkaline phosphatase (AKP)-streptavidin
(BD PharMingen) and developed with Sigmafast BCIP®/
NBT (Sigma). The reaction was stopped by rinsing the
plates with distilled water. Each well was then examined
for positive dots. The number of dots in each well was
counted by an ELISPOT reader system (AELVIS reader
system). IFN-γ-secreting cells were expressed as IFN-γ
spots per 1 × 106 cells. The IFN-γ spot values were
subtracted from the background, which was below 20
IFN-γ spots in 1 × 106 cells for each test.
Monoclonal antibody and dextramer staining
PBMCs were incubated with APC-labeled–HLA-A*0201
dextramer complexed to MYH9478-486 (QLFNHTMFI),
MYH9741-749 (VLMIKALEL), VIME78-87 (LLQDSVDFSL),
VIME225-233 (SLQEEIAFL) or ACTB266-274 (FLGMESCGI)
peptides (Immudex, Copenaghen, Denmark). The incuba-
tion was performed in fluorescence-activated cell sorter
(FACS) buffer (PBS containing 2% human AB serum) at
room temperature for 10 minutes, followed by washing
and further surface staining with FITC-labeled mAb to
CD8 (eBioscience, San Diego, CA, USA), phycoerythrin-
cyanine (PeCy)7-labeled mAb to PD-1 (eBioscience),
AlexaFluor700-labeled mAb to CD69, PECF594-labeled
mAb to HLA-DR, and a cocktail of labeled mAbs and re-
agents (APC-Cy7-labeled mAbs to CD4, CD14, CD16,
CD19, and CD56 (Biolegend)) and Fixable Viability Dye
eFluor 780 (eBioscience)) (dump channel), for 20 minutes
at 4°C. Dextramer+ cells were analyzed within a CD8+ cell
gate, whereas CD69+, HLA-DR+, or PD-1+ cells within
dextramer+CD8+ cells, after exclusion of B cells, mono-
cytes, natural killer T (NKT) cells, NK cells, CD4+ T cells
(dump channel). Cells were acquired with LSRFortessa
cytometer (Becton Dickinson) and analyzed with FlowJo
software version 7.5.5 (Tree star, Inc. San Carlos, CA,
USA).
Intracellular cytokine staining
Cytokine production was analyzed by intracellular stain-
ing (ICS) assay. PBMCs were incubated with or without
the relevant peptides (20 μg/mL) plus anti-CD28 mAb
(4 μg/mL) (BD Biosciences) and Protein Transport
Inhibitor Cocktail (500×) (Brefeldin A and Monensin)
(eBioscience), or with Cell Stimulation Cocktail (500×)
as positive control (PMA, ionomycin, brefeldin A and
monensin) (eBioscience), for 18 h at 37°C. Cells were
washed, and stained with APC-labeled-HLA-A*0201 dex
tramers complexed to corresponding peptides, PeCy7-la-
beled mAb to CD8 (Biolegend) and the dump channel
reagents. Cells were fixed and permeabilized using
Cytofix/Cytoperm solution (BD Biosciences) at 4°C for
20 minutes, re-washed with Perm Wash Buffer (BD Bio-
sciences), and stained with different combinations of
AlexaFluor700-labeled IL17A (Biolegend) and FITC-
labeled anti-IFN-γ (Biolegend) for 20 minutes at 4°C.
Cells were washed, acquired with LSRFortessa cytometer
(Becton Dickinson, Milano, Italy) and analyzed with
FlowJo software. IL-17, IFN-γ, or IL-17/IFN-γ-producing
cells were analyzed in CD8+dextramer+ cells after exclu-
sion of B cells, monocytes, NKT cells, NK cells, and CD4+
T cells (dump channel).
Cross-presentation of apoptotic cells
Cloned CD8+CD95+ T cells (10 to 100 × 106) were incu-
bated in the presence or absence of 14 μg/mL caspase 3-
inhibitor (C3I) (Z-DEVD-FMK), or a negative caspase
control (Ctr) (K, Z-FA-FMK) (BD Pharmingen) for 1 h
at 37°C in a 24-well plate. Then cells were induced to
apoptosis by incubation with 500 ng/mL anti-Fas (anti-
CD95 mAb (clone CH11), Upstate Biotechnology) for at
least 6 h. Apoptotic cells were determined as described
above. Finally, apoptotic T cells were isolated by positive
selection with annexin-V coupled to magnetic beads
(Miltenyi Biotec) as previously described. PBMCs were
double-stained with dextramers and mAb to CD8 and
cultured with iDCs that had been pulsed or not with
apoptotic cloned T cells. After 6 to 8 h, cells were tested
for their capacity to produce IL-17 and IFN-γ by ICS as
described [25,29].
Statistical analyses
The collected data were statistically analyzed using
GraphPad Prism version 4 software (GraphPad Software).
Comparison of the results for healthy donors (HDs) and
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patients was analyzed with the Mann-Whitney test.
Dextramer+ CD8+ T cell frequencies in CSF and PBMCs
were compared with the Wilcoxon matched pairs signed
rank test. Linear regression analysis was performed to
examine the correlation between tests and clinical data.
The differences were considered significant at P < 0.05.
Results
Multispecific CD8+ TEM cell responses to apoptotic
epitopes
Freshly isolated CD8+ T cells from 26 consecutive HLA-
A2+ patients with MS (Table 1) and 27 HDs were tested
for the capacity to form IFN-γ spots in an ELISPOT
assay within 4 to 6 h of contact either with 12 pools
containing a total of 90 synthetic HLA-A2-binding apop-
totic peptides (Additional file 1: Table S1) [25,29,35], or
with overlapping peptides spanning the entire sequence of
the MBP (Additional file 1: Table S2) [28]. Therefore, we
defined these CD8+ cells as TEM, on the basis of their cap-
acity to perform their effector functions promptly within a
few hours of antigenic stimulus. Each peptide was tested
in triplicate. The synthetic apoptotic peptides used were
prepared according to the sequence of caspase-cleaved
proteins that had been previously identified by the prote-
omic analyses of apoptotic T cells (for example, fragments
of ACTB, ROK, LAM1, MYH9, GDIS, VIME, PSA1, and
RLA) [25,29,35]. We found that the responses to apoptotic
epitope by IFN-γ+CD8+ TEM cells were significantly
higher and wider in patients than in HDs (Figure 1). In
particular, both the median number of IFN-γ spots formed
by CD8+ TEM cells from all MS patients or HDs in
response to the single peptide pool (responsiveness)
(Figure 1A), and the sum of IFN-γ spots formed in
response to the total peptide repertoire by a single
patient or HD (magnitude) (Figure 1B) were signifi-
cantly higher in MS patients than in HDs. The HLA-
restriction of these responses was demonstrated both
by blocking responses with an appropriate anti-class I
mAb and by determining that no response was ob-
served in HLA-A2– patients (data not shown). Not-
ably, the responses to MBP epitopes by IFN-γ+ TEM
cells were not significantly different between patients
and HDs (Additional file 3: Figure S1). No correlation
was found between the ELISPOT responses either to
apoptotic epitopes, or to MBP epitopes and EDSS,
MRI grading, or clinical course of therapy (data not
shown).
Accumulation of apoptotic epitope-specific CD8+ T cells
in CSF correlates with MS disability
First, we enumerated apoptotic epitope-specific CD8+ T
cells in the peripheral blood of 15 HLA-A2+ MS patients
(providing adequate numbers of PBMCs to extend the
analyses to dextramer staining), as compared with 10 HDs,
Figure 1 CD8+ T cell multispecificity to apoptotic epitopes in
healthy donors and multiple sclerosis patients. (A) Mean
number of IFN-γ spots formed by fresh CD8+ T effector memory
(TEM) cells (by enzyme-linked immunospot assay) in response to 12
pools (see Additional file 1: Table S1A-C) of apoptotic self-epitopes
in 26 HLA-A2+ patients with multiple sclerosis (MS) (dark bars) or 27
HLA-A2+ healthy donors (HDs) (clear bars). n.s., not significant.
(B) Sum of IFN-γ spots formed by fresh CD8+ TEM cells in response
to all pools (see Additional file 1: Table S1A-C) of apoptotic
self-epitopes in the single patients or HDs. Each circle represents a
single patient or a single HD. Statistical analysis was performed with
the Mann-Whitney test. RLA, 60S acidic ribosomal protein P2; PSA,
proteosome component C3; VIME, vimentin; GDIS, GDP dissociation
inhibitor 2; Myh9, non-muscle myosin heavy chain 9; LAM1,
lamin B1; ROK, heterogeneous nuclear ribonucleoprotein; ACTB,
actin cytoplasmic 1.
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by using dextramers of HLA-A*0201 molecules complexed
to apoptotic (ACTB266-274, MYH9478-486, MYH9741-749,
VIME78-87, or VIME225-233) peptides (Figure 2). Control
dextramers complexed to a non-natural irrelevant peptide
were unable to stain CD8+ T cells in all samples tested (data
not shown). All analyzed patients presented significantly
higher frequencies of peripheral dextramer+CD8+ T cells
than HDs, in terms of both responsiveness and magnitude
(Figure 2A,C,D). In addition, a notable proportion of these
apoptotic epitope-specific CD8+ T cells expressed late acti-
vation markers, namely HLA-DR and PD-1, suggesting that
they are experienced T cells (Figure 2B,E). The percentage
of apoptotic T cells circulating in PBMCs tended to be
more elevated in patients than in HDs, though in a
Figure 2 Detection of peripheral CD8+ T cells specific to apoptotic epitopes in healthy donors and multiple sclerosis patients directly
in vivo. (A) Representative flow cytometry analysis of peripheral blood mononuclear cells, from a multiple sclerosis (MS) patient and a healthy
donor (HD), were stained with a phycoerythrin-cyanine (PeCy7)-labeled mAb to CD8, allophycocyanin (APC)-labeled-HLA-A*0201 dextramers
expressing the indicated apoptotic peptides, and the dump channel APC-Cy7-labeled reagents so as to exclude CD4+ T cells, monocytes, B cells,
natural killer (NK) cells and dead cells from the analysis. Contour plot analyses show the percentage of CD8+dextramer+ cells. The percentage of
cells is indicated in the appropriate quadrant. (B) Representative flow cytometry analysis of PBMCs stained with a pool of APC-labeled–HLA-A*0201
dextramer expressing relevant peptides, fluorescein isothiocyanate-labeled mAb to CD8, PeCy7-labeled mAb to PD-1, AlexaFluor700-labeled mAb to
CD69, PECF594-labeled mAb to HLA-DR, and dump channel labeled reagents. Dot plot analyses show percentages of CD69+, HLA-DR+, or PD-1+ cells
in gated CD8+dextramer+ cells. The percentage of cells is reported in each quadrant. (C) Percentage of CD8+dextramer+ cells specific to a single
epitope in 10 HLA-A2+ HD and 15 HLA-A2+ patients (each symbol represents the percentage of CD8+dextramer+ cells specific to a single epitope in
HDs or patients). (D) Sum of the percentages of all CD8+dextramer+ T cells detected in the single patient or HD (each symbol represents the sum of
percentages of the five dextramers tested in the single individual). (E) Percentages of CD69+, HLA-DR+, or PD-1+ cells in CD8+dextramer+ T cells from
MS patients. Statistical analysis was performed with the Mann-Whitney test. MYH9, non-muscle myosin heavy chain 9; VIME, vimentin; ACTB,
actin cytoplasmic 1.
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non-significant manner, thus, tempting us to suggest
the possible relationship between apoptotic T cells and
the emergence of CD8+ T cells specific to apoptotic
epitopes (Additional file 4: Figure S2A,B) [25,29,35]:
additional analyses in a larger cohort of patients are re-
quired to confirm this possibility. However, no correla-
tions were observed between the frequency of peripheral
dextramer+CD8+ T cells or expression of activation
markers, and EDSS or MRI grading of MS patients tested
(data not shown). Similar analyses were performed at the
level of CSF-derived mononuclear cells obtained from
seven MS patients. Because of the tiny number of cells
isolated from the CSF, we chose to detect only MYH9741-
749-specific CD8
+ T cells by dextramers, on the basis of
the observation that they were frequent in the periph-
ery. Notably, among the MS patients tested, the
frequency of MYH9741-749-specific CD8
+ T cells was
significantly higher in the CSF than in the periphery
(Figure 3A,B). Importantly, the frequencies of CSF-derived
CD8+ T cells specific to the apoptotic MYH9741-749 epi-
tope were directly correlated with the disease disability
(Figure 3C), suggesting that these cells are recruited in the
inflammatory site and that they participate in the central
CNS immunopathology.
Polyfunctional (IFN-γ and IL-17) response by apoptotic
epitope-specific CD8+ T cells
To determine whether subsets with different effector
functions were present within the total CD8+dextramer+
T cells, we analyzed the frequencies of freshly isolated
CD8+dextramer+ T cells that produced IFN-γ and/or
IL-17 within a few hours of contact with the relevant
peptides and optimal concentrations of anti-CD28 mAb,
which served as a surrogate co-stimulatory signal. Un-
detectable cytokine production was observed when
apoptotic epitope-specific CD8+dextramer+ T cells of
10 HLA-A2+ HDs were stimulated with this procedure
(data not shown). By contrast, all apoptotic epitope-spe-
cific CD8+dextramer+ cells (derived from the peripheral
blood of 12 MS patients) produced the cytokines tested in
response to the relevant epitopes (polyfunctional re-
sponses) (Figure 4A,B) [6]. Peripheral dextramer+CD8+
TEM cells particularly produced only IFN-γ (type-1 cells)
or IL-17 (type-17 cells), whereas a minority of them simul-
taneously produced the two cytokines (type-1/17 cells) in
response to relevant single epitopes (Figure 4B). To valid-
ate the antigen specificity of these peripheral dextramer+
cells, PBMCs from six randomly selected patients were
cultured in the presence of the relevant peptide for 15
days in IL-2-conditioned medium in vitro, then stained
with the relevant dextramer and anti-CD8, and tested for
their capacity to respond to autologous PBMCs plus
peptide. Under these conditions, the apoptotic antigen-
specific CD8+ T cells continued to produce notable
amounts of either IFN-γ or IL-17 in an antigen-specific
manner, clearly confirming the antigen-specificity of these
cells (Figure 4C). However, no correlation between the fre-
quency of these peripheral cytokine-producing TEM cells
or the magnitude of the response by the cultured CD8+ T
cells and any clinical parameter tested was observed (data
not shown). To determine whether the lack of these corre-
lations in the periphery was because of the recruitment of
the majority of these cells at the level of the inflammatory
site, we investigated the function of CSF-derived apoptotic
epitope-specific CD8+ T cells. Because the tiny number of
apoptotic epitope-specific CD8+dextramer+ T cells derived
from the CSF did not allow prompt detection of cytokine
production, we determined their functional potential upon
two rounds of stimulation with autologous irradiated
PBMCs in the presence of the relevant peptide for 30 days
in IL-2-conditioned medium in vitro. Next, the cultured
CSF cells were stained with the relevant dextramer and
Figure 3 Apoptotic epitope-specific CD8+ T cells are accumulated in cerebrospinal fluid and correlate with disease disability. (A)
Representative flow cytometry analyses of cerebrospinal fluid (CSF)-derived mononuclear cells from a multiple sclerosis (MS) patient. Cells were
double-stained with a mAb to CD8 and dextramers expressing the indicated non-muscle myosin heavy chain 9 (MYH9) peptides. Dot plot
analyses show the percentage of CD8+pentamer+ cells. The percentage of cells is indicated in the appropriate quadrant. (B) Percentages of
peripheral blood (PB)- or CSF-derived CD8+dextramer+ cells isolated from seven HLA-A2+ MS patients. Statistical analysis was performed with the
Wilcoxon matched pairs signed rank test. (C) Correlation between percentages of CSF-derived CD8+dextramer+ cells and disability, calculated on
the Expanded Disability Status Scale (EDSS) (linear regression analysis).
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anti-CD8. They were tested for their capacity to respond
to autologous PBMCs plus peptide. Under these condi-
tions, we obtained a strong expansion of antigen-specific
CD8+ T cells producing either IFN-γ or IL-17, suggesting
that these cells are represented by CSF-derived memory
cells selectively polarized towards a type-1 or type-17 pro-
file (Figure 5A,B). Importantly, the CSF-derived apoptotic
epitope-specific CD8+ T cells producing IL-17 were dir-
ectly correlated with the EDSS (Figure 5C).
Cross-presentation of apoptotic T cells ex vivo
To verify if the cross-presentation mechanism plays a role
in the activation of apoptotic epitope-specific CD8+ T
cells, we evaluated the capacity of fresh dextramer+CD8+
TEM cells to produce IFN-γ or IL-17 within a few h of
contact with HLA-A2+ DCs that had been previously
pulsed with apoptotic T cells. Under these conditions,
dextramer+CD8+ TEM cells promptly produced IFN-γ or
IL-17 ex vivo (Figure 6A). The cross-presentation resulted
in a marked decrease in IFN-γ or IL-17 production when
apoptotic cells had been previously treated with the select-
ive C3I, but not when treated with an appropriate negative
Ctr (Figure 6A). This phenomenon was independently
confirmed in five patients (Figure 6B). Although DCs are
known to endogenously express high levels of the ubiqui-
tous (long-lived) cellular proteins (ACTB, ROK, LAM1,
MYH9, VIME, or PSA1) [25], DCs alone were unable
to directly stimulate the related specific CD8+ T cells,
thus supporting the concept that cross-presentation of
these proteins requires caspase-dependent cleavage
(Figure 6A,B).
Discussion
Here we demonstrate for the first time that the multi
specificity, magnitude, and polyfunctional (type-1 and
type-17) strength of CD8+ TEM cell responses directed
Figure 4 Polyfunctional CD8+ T effector memory cells specific to apoptotic epitopes in multiple sclerosis patients. (A) Representative
flow cytometry analysis of peripheral blood mononuclear cells from a multiple sclerosis (MS) patient. Cells were incubated with or without the
relevant peptides plus anti-CD28 mAb for 18 h at 37°C. Then cells were stained with dextramers complexed to corresponding peptides,
phycoerythrin-cyanine-labeled mAb to CD8 and the dump channel reagents and processed for the detection of IL-17 and IFN-γ, by intracellular
staining (ICS) assay with the relevant mAbs. Dot plot analyses are gated on CD8+dextramer+ cells and show percentages of cytokine-producing
cells. The percentage of cells is reported in each quadrant. (B) Percentages of CD8+dextramer+ cells specific to the corresponding peptides
producing IL-17, IFN-γ, or both within 18 h of contact with the relevant peptides in the 12 patients analyzed. (C) Representative flow cytometry
analysis of an antigen-specific T cell line obtained upon 15 days stimulation with the non-muscle myosin heavy chain 9 (MYH9)478-486 epitope
and IL-2. Cells were stained with mAb to CD8, the indicated dextramers, and were then stimulated or not with the relevant soluble peptide plus
anti-CD28 mAb for detecting IL-17 and IFN-γ production by ICS assay, as described above. Contourplot analyses are gated on CD8+dextramer+
cells and show percentages of cytokine-producing cells. Similar results were obtained in six patients tested with different apoptotic epitopes.
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to apoptotic self-epitopes were significantly higher in MS
patients as compared with HDs. Importantly, the fre-
quencies of the CSF-derived apoptotic epitope-specific
CD8+dextramer+ T cells were significantly higher than
those of the peripheral counterparts, and correlated with
the disease disability. These CSF-derived apoptotic anti-
gen-specific CD8+ T cells significantly expanded and pro-
duced high levels of pro-inflammatory cytokines (IFN-γ
and IL-17) in response to antigenic stimulus in vitro, and
those with the potential to produce IL-17 in response to
the relevant apoptotic epitope were correlated with the
disease disability. By contrast, the peripheral apoptotic
antigen-specific dextramer+CD8+ TEM cells that produced
IFN-γ or IL-17 in response to the apoptotic epitopes
analysed ex vivo, as well as upon 15 d of antigen-stimula-
tion in vitro, did not correlate with any clinical parameter.
Altogether these data suggest that apoptotic self-antigen-
specific T cells with strong inflammatory potential are
recruited at the level of the inflammatory site, where they
largely expand under certain inflammatory conditions and
may contribute, through the production of high levels of
inflammatory cytokines, to immunopathology and chronic
evolution of MS. In addition, these results emphasize the
concept that the CSF-confined immune cell responses re-
flect the immunologic setting at the level of an inflamma-
tory process occurring in the CNS, to a greater extent
than those in the periphery.
Notably, our finding of no correlation between MBP-
specific responses and MS does not lend support to de-
fining MBP as a major immunological target in MS.
However, it is unlikely that the T cell responses to apop-
totic antigens represent the event initiating the CNS
pathology. Indeed, our previous studies demonstrated
that these responses require stimulation by a consider-
able number of apoptotic cells that derive from pre-
existing activated T cells, such as the virus-specific T
cells that are generated during HIV or HCV infections
[25,29]. In the case of MS, the primary activated T cells
may be specific for (but as of yet unknown) CNS-derived
self-antigens or even pathogens (correlated with MS)
Figure 5 Cerebrospinal fluid-derived apoptotic epitope-specific CD8+ T cells producing IL-17 are correlated with disability in multiple
sclerosis. (A) Representative flow cytometry analysis of an antigen-specific T cell line obtained upon 30 days of stimulation of cerebrospinal fluid
(CSF)-derived mononuclear cells with the non-muscle myosin heavy chain 9 (MYH9)741-749 epitope and IL-2. Cells were stained with mAb to CD8, the
indicated dextramers, and were then stimulated or not with the relevant soluble peptide plus anti-CD28 mAb for detecting IL-17 and IFN-γ production
by intracellular staining (ICS) assay. Contour plot analyses are gated on CD8+dextramer+ cells and show percentages of cytokine-producing cells.
(B) Percentage of CSF-derived MYH9741-749-specific T cell lines obtained from seven multiple sclerosis (MS) patients, as indicated in (A) producing IL-17
and IFN-γ in response to the relevant apoptotic peptide. CSF-derived T cell lines were stained with mAb to CD8, the indicated dextramers, and
stimulated or not with the relevant soluble peptide plus anti-CD28 mAb for detecting IL-17 and IFN-γ production by ICS assay. (C) Correlation between
percentage of CSF-derived MYH9741-749-specific T cell lines producing IL-17 and disability, as determined by the Expanded Disability Status Scale (EDSS)
(linear regression analysis).
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that start the immunological cascade leading to MS, and
consequently may induce apoptotic antigen-specific T
cells by providing them with the first boost of apoptotic
antigens. According to this scenario, the apoptotic anti-
gen-specific T cell responses would represent an epiphe-
nomenon of the responses that have initiated the
inflammatory program. They may strongly contribute to
amplify and sustain CNS damage through a vicious
cycle, providing continuous waves of apoptotic antigens
upon performing their pro-inflammatory activity, as in-
dicated by both the substantial accumulation of these
cells with strong inflammatory potential in CSF and their
correlation with the disease disability. The finding that
the same responses are operative in various chronic
infections (HIV and HCV [25,29]), and in different auto-
immune diseases, such as rheumatoid arthritis (manu-
scripts in preparation), suggests that they may support a
general mechanism in several immunopathological con-
ditions. It will be of interest to verify whether a genetic
background predisposing to autoimmunity harbors vari-
ants that may foster this mechanism.
The observation that caspase-cleavage of apoptotic an-
tigens is required to activate the related CD8+ TEM cells
by cross-presentation ex vivo indicates that these auto-
reactive CD8+ T cells may contribute to the CNS dam-
age through the production of pro-inflammatory IFN-γ
and IL-17 cytokines upon cross-presentation of the huge
number of CD40L+ apoptotic cells (infiltrating inflamed
tissues [39]), rather than by the direct killing of CNS
cells [10], [25,34,36]. We cannot exclude the possi-
bility that apoptotic CNS cells (for example, oligoden-
drocytes) may also amplify this phenomenon in an
inflammatory context, because they might potentially
generate similar caspase-cleaved antigenic fragments.
In addition, other mechanisms may contribute to
establishing the chronic immunopathological processes. Re-
cently, the increased frequency of EBV-specific CD8+ T cells
interacting with EBV-infected plasma cells in white matter
has been associated with the active phase of MS [40]. More-
over, several independent memory Tcells (for example, those
that are specific to a multitude of pathogens normally circu-
lating in the lymphoid tissues), which are stimulated in a by-
stander fashion, can be recruited in an inflammatory site
where they can perform effector functions [41-43].
Finally, our results may have clinical implications. Fur-
ther studies are needed to ascertain whether polyfunctional
CD8+ T cells that are specific to apoptotic epitopes could
predict relapses in MS or worsening of the disease. Ac-
cordingly, appropriate therapies could be administered
earlier and, in so doing, limit the disease severity in pa-
tients who are expected to experience the clinical evolution
of MS and neurological disability.
Figure 6 Cross-presentation of naturally processed apoptotic epitopes to the related CD8+ TEM cells by dendritic cells. (A) One
representative of five experiments in which peripheral blood mononuclear cells from one MS patient were double-stained with mAb to CD8 and
dextramers complexed with the indicated apoptotic epitope. These cells were then cultured with autologous dendritic cells (DCs) that had been
pulsed or not with the relevant soluble peptide, apoptotic cloned T cells (ACs = apoptotic cells), ACs previously treated with a negative caspase
control (Ctr = Z-FA-FMK), or ACs previously treated with the caspase 3 inhibitor (C3I = Z-DEVD-FMK). After 18 h, CD8+dextramer+ cells were
tested for their capacity to produce the different cytokines indicated by the intracellular staining assay. Dot plots are gated on CD8+dextramer+
cells and show percentages of the different cytokine-producing cells in each quadrant. (B) Cumulative experiments in five independent patients,
performed as described in (A), showing the mean percentages of cells producing IL-17 (solid bars) and IFN-γ (open bars) in CD8+dextramer+ cells
in response to the indicated stimuli: autologous DCs alone; DCs pulsed with the vimentin (VIME)78-87 peptide; DCs pulsed with ACs, which had
been previously treated with a negative caspase control (Z-FA-FMK); or DCs pulsed with ACs, which had been previously treated with the
C3I (Z-DEVD-FMK).
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Conclusions
The demonstration that mixed polyfunctional (type-1
and -17) CD8+ TEM cells specific for apoptotic T cell-as-
sociated self-epitopes are recruited in the CSF of MS pa-
tients and are associated with the clinical score of
disease disability, suggests that apoptotic self-antigen-
specific T cells with strong inflammatory potential largely
expand at the level of the inflammatory site, and may
contribute, through the production of high levels of
inflammatory cytokines, to MS immunopathology. Cross-
presentation of caspase-cleavage of apoptotic antigens is
required to activate these autoreactive CD8+ TEM cells ex
vivo, suggesting that the latter may participate to the CNS
damage through the production of pro-inflammatory IFN-
γ and IL-17 cytokines upon cross-presentation of the huge
number of apoptotic cells present in the inflamed tissue.
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